Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity.
about
Cholesterol-enriched diet causes age-related macular degeneration-like pathology in rabbit retinaMicroarray analysis on human neuroblastoma cells exposed to aluminum, β(1-42)-amyloid or the β(1-42)-amyloid aluminum complex.Amyloid-beta and Alzheimer's disease: the role of neprilysin-2 in amyloid-beta clearanceProteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process.Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain.Altered NEP2 expression and activity in mild cognitive impairment and Alzheimer's disease.Distribution and expression of picalm in Alzheimer diseaseGinsenoside Rg1 decreases Aβ(1-42) level by upregulating PPARγ and IDE expression in the hippocampus of a rat model of Alzheimer's disease.Prion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid-β levels and Braak stageBIN1 is decreased in sporadic but not familial Alzheimer's disease or in aging.Altered enzymatic activity and allele frequency of OMI/HTRA2 in Alzheimer's diseaseNitric oxide-mediated regulation of β-amyloid clearance via alterations of MMP-9/TIMP-1Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.Transcriptional regulation of insulin-degrading enzyme modulates mitochondrial amyloid β (Aβ) peptide catabolism and functionality.Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease.Gene therapy in Alzheimer's disease - potential for disease modificationNeprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's DiseaseDisturbed Matrix Metalloproteinase Pathway in Both Age-Related Macular Degeneration and Alzheimer's DiseaseDeciphering the molecular profile of plaques, memory decline and neuron loss in two mouse models for Alzheimer's disease by deep sequencing.Current therapies and new strategies for the management of Alzheimer's disease.Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease.Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes.Neprilysin facilitates adipogenesis through potentiation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway.Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?Mercury Reduces the Enzymatic Activity of Neprilysin in Differentiated SH-SY5Y Cells.Sex Hormone Decline and Amyloid β Synthesis, Transport and Clearance in the Brain.Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes.Molecular Pathogenesis of Alzheimer's Disease: An Update.Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-β (Aβ) Plaque Load and Aβ-Synthesizing and Aβ-Degrading Enzymes in Frontal Cortex.Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes.Aggregation, impaired degradation and immunization targeting of amyloid-beta dimers in Alzheimer's disease: a stochastic modelling approach.Genetic variation in MME in relation to neprilysin protein and enzyme activity, Aβ levels, and Alzheimer's disease risk.Major amyloid-β-degrading enzymes, endothelin-converting enzyme-2 and neprilysin, are expressed by distinct populations of GABAergic interneurons in hippocampus and neocortex.Tau hyperphosphorylation induces oligomeric insulin accumulation and insulin resistance in neurons.The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial.Curcumin Ameliorates Memory Decline via Inhibiting BACE1 Expression and β-Amyloid Pathology in 5×FAD Transgenic Mice.Copper(I) and copper(II) inhibit Aβ peptides proteolysis by insulin-degrading enzyme differently: implications for metallostasis alteration in Alzheimer's disease.Neprilysin in the cerebrospinal fluid and serum of patients infected with HIV1- subtypes C and B.The ageing immune system and its clinical implicationsNeprilysin Protects against Cerebral Amyloid Angiopathy and Aβ-Induced Degeneration of Cerebrovascular Smooth Muscle Cells
P2860
Q21260371-4C7B0749-F12D-41CD-83D2-5F64B7740F08Q33813237-F8E94816-99A8-4062-9C64-B72336B7D8ECQ34039695-9F8503BA-0C74-431B-B67F-DA73CDA5DCC5Q34110227-F1EFD0FE-CE65-4486-9398-DF9712CA3346Q34130147-DBE84FAB-1D49-45BA-840B-0FEDB510EC78Q34225229-DFCE8D96-452B-44DD-8117-A598906C8461Q34472845-DA7B26DB-FF1F-4C10-8748-497978647651Q34632017-9F2B9C61-5B36-4454-BCE4-D8598F387664Q34663576-4F42123B-DAF8-4B4B-879D-2C02DD4F9B07Q35036731-5EC4E9D3-2D1C-4D6D-A079-EFB8BE7A2DFAQ35585384-A96E938B-86C1-45C4-83C5-AE89E51C5B24Q36735832-5B321250-3E7D-403E-9B5B-E1168DB6992DQ36764094-B06ABF4C-7884-40ED-BF29-5DD7291626B9Q36812453-5B601F19-6CBC-4D66-B67D-10AE21B0743CQ37224550-CC81023F-A4AE-4F33-98CF-7C034D1DE4A6Q37295252-85B06175-D2DF-4194-8019-46805B34C62FQ37408544-AE46F3DF-00B4-4DD5-A983-574140BBCDB5Q37618360-7858D1FA-1AB7-4349-B92E-3A235455239EQ37718997-7177E605-84CE-4DEB-A252-B476E55981D5Q37770005-EEBA0559-A60B-4561-9C40-B2907D4FB660Q38256360-2EC5DD42-87D3-4364-9638-2C4E5B582EBEQ38259551-DF85AEDF-AE12-47FB-9BB9-3A6CBF4C95D4Q38714743-6ACE9776-C36F-402A-AAE2-A9177996CBA5Q38869928-C33E16B4-C7E0-451B-9A7C-04520DC06C49Q38910551-FFB3D8F2-2117-472F-A4BD-D8B2431CCBD9Q38955319-572233F9-5299-4592-9875-9B8BAD1518B8Q39135845-D751B343-CA76-4A91-AC8E-BDFA58D202B7Q39355183-A24EF97C-A86C-4036-99CB-B594BFC3A3A6Q40032135-368B7319-6128-4D64-A73D-C15FEA82E923Q41840991-EBA9E0C4-8123-4613-B314-EE996E468F8AQ42223118-261CDAAF-BC9F-4767-B4F2-2E71CDC6172CQ42561537-33712959-6D43-461B-BB0B-67B892530735Q46152909-F6E5DEF4-35A7-4417-B91A-C44400CDED98Q47623946-11E58C9C-9FFD-4AF3-B5C7-08833D30C00CQ47923008-E3A6043A-4E32-4D92-B7DA-01F0CF693434Q48881749-363A20F5-8D5D-4624-AE3D-FA27E3F8FCB9Q51608953-875ED48F-0D42-46F4-A376-3C7DC76A3B7BQ52730355-9B282E46-97DA-4255-87CE-9E2C5F856A66Q58045474-277597F1-9DA3-4F21-A37C-FBC19503B016Q58477330-911005BF-B1BD-409A-852B-4A64CBA607CA
P2860
Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Neprilysin and insulin-degradi ...... relation to disease severity.
@en
Neprilysin and insulin-degradi ...... relation to disease severity.
@nl
type
label
Neprilysin and insulin-degradi ...... relation to disease severity.
@en
Neprilysin and insulin-degradi ...... relation to disease severity.
@nl
prefLabel
Neprilysin and insulin-degradi ...... relation to disease severity.
@en
Neprilysin and insulin-degradi ...... relation to disease severity.
@nl
P2093
P1476
Neprilysin and insulin-degradi ...... relation to disease severity.
@en
P2093
James Scott Miners
Shabnam Baig
P304
P356
10.1097/NEN.0B013E3181AFE475
P577
2009-08-01T00:00:00Z